Patient-reported outcomes are changing the landscape in oncology care: Challenges and opportunities for payers

American Health and Drug Benefits

Volumn 6, Issue 5, 2013, Pages

  Zagadailov, Erin ^a   Fine, Michael ^b   Shields, Alan ^c  

^a Searle   (United States)

^b Health Net of California   (United States)

^c ADELPHI REAL WORLD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMATINIB; IRINOTECAN; LEUPRORELIN; MITOXANTRONE; PACLITAXEL; PLACEBO; RUXOLITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; COLORECTAL TUMOR; DISEASE SEVERITY; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LUNG NON SMALL CELL CANCER; MYELOFIBROSIS; ONCOLOGY; OUTCOME ASSESSMENT; PANCREAS TUMOR; PATIENT DECISION MAKING; PATIENT REPORTED OUTCOME; PREDICTIVE VALIDITY; PROGNOSIS; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SELF REPORT; SHORT FORM 36; SYMPTOM ASSESSMENT; TREATMENT RESPONSE;

EID: 84880582346     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. US Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed April 19, 2013.
2. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25:535-552.
3. Marquis P, Caron M, Emery M, et al. The role of health-related quality of life data in the drug approval processes in the US and Europe: a review of guidance documents and authorizations of medicinal products from 2006 to 2010. Pharm Med. 2011;25:147-160.
4. Gnanasakthy A, Mordin M, Clark M, et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012;15:437-442.
5. Hao Y. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert Rev Pharmacoecon Outcomes Res. 2010;10: 407-420.
6. Shields A, Gwaltney C, Tiplady B, et al. Grasping the FDA's PRO guidance: what the agency requires to support the selection of patient-reported outcome instruments. Applied Clin Trials. 2006;15:69-77.
7. Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health. 2009;12:419-429.
8. Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force report. Value Health. 2009;12:1075-1083.
9. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14:967-977.
10. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part II-assessing respondent understanding. Value Health. 2011;14:578-588.
11. Bruner DW, Bryan CJ, Aaronson N, et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol. 2007;25:5051-5057.
12. Gondek K, Sagnier PP, Gilchrist K, Woolley JM. Current status of patient--reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol. 2007;25:5087-5093.
13. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
14. Kitchen H, Rofail D, Caron M, Emery MP. Oncology patient-reported claims: maximising the chance for success. Ecancermedicalscience. 2011;5:212.
15. Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007;25:5133-5140.
16. Doward L, Gnanasakthy A, Baker M. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes. 2010;8:89-97.
17. Hycamtin [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
18. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658-667.
19. Deisseroth A, Kaminskas E, Grillo J, et al. US Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high risk myelofibrosis. Clin Cancer Res. 2012;18:3212-3217.
20. Jakafi [prescribing information]. Wilmington, DE: Incyte Corporation; 2012.
21. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
22. Falcone CR, Levy RS. Approval of Jakafi (ruxolitinib) based on a home-grown, patient-reported outcome instrument: a case study. Regulatory Focus website. June 2012. www.raps.org/focus-online/quality-and-compliance/quality-and-compliance--article/article/1854/approval-of-jakafi-ruxolitinib-based-on-a-home-grown-patient-reported-outcome-i.aspx. Accessed January 7, 2013.
23. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199-1203.
24. Rock EP, Scott JA, Kennedy DL, et al. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J Natl Cancer Inst Monogr. 2007;37:27-30.
25. Xcenda. Patient-reported outcomes in oncology focus group. April 17, 2012. Unpublished data.